Metformin-an adjunct antineoplastic therapy-divergently modulates tumor metabolism and proliferation, interfering with early response prediction by 18F-FDG PET imaging

Journal of Nuclear Medicine

Volumn 54, Issue 2, 2013, Pages 252-258

  Habibollahi, Peiman ^a   Van Den Berg, Nynke S ^a   Kuruppu, Darshini ^a   Loda, Massimo ^b   Mahmood, Umar ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

AMPK; Metformin; Proliferation imaging; Tumor metabolic imaging

Indexed keywords

3' FLUOROTHYMIDINE F 18; ADENOSINE MONOPHOSPHATE ACTIVATED PROTEIN KINASE; ANNEXIN; EDOXUDINE; FLUORODEOXYGLUCOSE F 18; METFORMIN; PROPIDIUM IODIDE; PROTEIN KINASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL CULTURE; CANCER INVASION; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL STRAIN HT29; COLON CANCER; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG CYTOTOXICITY; DRUG UPTAKE; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; FLOW CYTOMETRY; GLUCOSE TRANSPORT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; METFORMIN; MICE; MICE, NUDE; MODELS, BIOLOGICAL; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; TIME FACTORS;

EID: 84873547281     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.107011     Document Type: Review

References (32)

1. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005;330:1304-1305.
2. Wright JL, Stanford JL. Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. Cancer Causes Control. 2009;20:1617-1622.
3. Lee JH, Kim TI, Jeon SM, Hong SP, Cheon JH, Kim WH. The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus. Int J Cancer. 2012;131:752-759.
4. IRCCS San Raffaele. Combination chemotherapy with or without metformin hydrochloride in treating patients with metastatic pancreatic cancer (PACT-17). Available at: http://clinicaltrials.gov/ct2/show/NCT01167738. 2012. Accessed December 20, 2012.
5. Swiss Group for Clinical Cancer Research. Metformin hydrochloride as firstline therapy in treating patients with locally advanced or metastatic prostate cancer. Available at: http://clinicaltrials.gov/ct2/show/NCT01243385. 2012. Accessed December 20, 2012.
6. Ozmosis Research Inc. A trial of standard chemotherapy with metformin (vs placebo) in women with metastatic breast cancer. Available at: http://clinicaltrials. gov/ct2/show/NCT01310231. 2012. Accessed December 20, 2012.
7. Buzzai M, Jones RG, Amaravadi RK, et al. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res. 2007;67:6745-6752.
8. Green AS, Chapuis N, Maciel TT, et al. The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation. Blood. 2010;116:4262-4273.
9. Liu B, Fan Z, Edgerton SM, et al. Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle. 2009;8:2031-2040.
10. Ben Sahra I, Laurent K, Loubat A, et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene. 2008;27:3576-3586.
11. Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 2009;69:7507-7511.
12. Alimova IN, Liu B, Fan Z, et al. Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle. 2009;8: 909-915.
13. Algire C, Amrein L, Zakikhani M, Panasci L, Pollak M. Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase. Endocr Relat Cancer. 2010;17:351-360.
14. El-Mir MY, Nogueira V, Fontaine E, Averet N, Rigoulet M, Leverve X. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem. 2000;275:223-228.
15. Hardie DG. AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol. 2007;8:774-785.
16. Shackelford DB, Shaw RJ. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer. 2009;9:563-575.
17. Kahn BB, Alquier T, Carling D, Hardie DG. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab. 2005;1:15-25.
18. 18F-FDG bowel uptake in patients treated with metformin. Eur J Nucl Med Mol Imaging. 2008;35:95-99.
19. 18F-FDG uptake associated with metformin after stopping the drug. Eur J Nucl Med Mol Imaging. 2010;37:1011-1017.
20. Viljanen AP, Virtanen KA, Jarvisalo MJ, et al. Rosiglitazone treatment increases subcutaneous adipose tissue glucose uptake in parallel with perfusion in patients with type 2 diabetes: a double-blind, randomized study with metformin. J Clin Endocrinol Metab. 2005;90:6523-6528.
21. Zhang XF, Tan BK. Effects of an ethanolic extract of Gynura procumbens on serum glucose, cholesterol and triglyceride levels in normal and streptozotocininduced diabetic rats. Singapore Med J. 2000;41:9-13.
22. Bodmer M, Meier C, Krahenbuhl S, Jick SS, Meier CR. Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis. Diabetes Care. 2008;31:2086-2091.
23. Decensi A, Puntoni M, Goodwin P, et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila). 2010;3:1451-1461.
24. Vander Heiden MG. Targeting cancer metabolism: a therapeutic window opens. Nat Rev Drug Discov. 2011;10:671-684.
25. Winder WW, Hardie DG. Inactivation of acetyl-CoA carboxylase and activation of AMP-activated protein kinase in muscle during exercise. Am J Physiol. 1996;270:E299-E304.
26. 59AMP-activated protein kinase activity in the heart and its role in inhibiting acetyl-CoA carboxylase during reperfusion following ischemia. Biochim Biophys Acta. 1996;1301:67-75.
27. Martin-Castillo B, Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA. Metformin and cancer: doses, mechanisms and the dandelion and hormetic phenomena. Cell Cycle. 2010;9:1057-1064.
28. Jalving M, Gietema JA, Lefrandt JD, et al. Metformin: taking away the candy for cancer? Eur J Cancer. 2010;46:2369-2380.
29. Li J, Benashski SE, Venna VR, McCullough LD. Effects of metformin in experimental stroke. Stroke. 2010;41:2645-2652.
30. 18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res. 2003;63:3791-3798.
31. Pantaleo MA, Nannini M, Maleddu A, et al. Conventional and novel PET tracers for imaging in oncology in the era of molecular therapy. Cancer Treat Rev. 2008;34:103-121.
32. 18F]FDG PET in human ovary cancer xenografts in mice. PLoS One. 2010;5:e12965.